Pharmacokinetic/pharmacodynamic modeling of in vitro activity of azithromycin against four different bacterial strains

International Journal of Antimicrobial Agents

Volumn 29, Issue 3, 2007, Pages 263-270

  Treyaprasert, Wanchai ^a,b   Schmidt, Stephan ^b   Rand, Kenneth H ^c   Suvanakoot, Uthai ^a   Derendorf, Hartmut ^b  

^a CHULALONGKORN UNIVERSITY   (Thailand)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c Department of Clinical and Health Psychology   (United States)

Author keywords

Azithromycin; In vitro activity; Modeling

Indexed keywords

AZITHROMYCIN; PENICILLIN G;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM; CONCENTRATION RESPONSE; CONTROLLED STUDY; CURVE FITTING; DRUG EFFICACY; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; MORAXELLA CATARRHALIS; NONHUMAN; NONLINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BACTERIA; ERYTHROMYCIN; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; MORAXELLA (BRANHAMELLA) CATARRHALIS; MORAXELLACEAE INFECTIONS; PENICILLIN RESISTANCE; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE;

EID: 33846915413     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2006.08.049     Document Type: Article

References (29)

1. Mueller M., de la Pena A., and Derendorf H. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob Agents Chemother 48 (2004) 369-377
2. Nolting A., Dalla Costa T., Rand K.H., and Derendorf H. Pharmacokinetic-pharmacodynamic modeling of the antibiotic effect of piperacillin in vitro. Pharm Res 13 (1996) 91-96
3. Liu P., Muller M., and Derendorf H. Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents 19 (2002) 285-290
4. Dalla Costa T., Nolting A., Rand K., and Derendorf H. Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations. Int J Clin Pharmacol Ther 35 (1997) 426-433
5. de la Pena A., Grabe A., Rand K.H., et al. PK-PD modelling of the effect of cefaclor on four different bacterial strains. Int J Antimicrob Agents 23 (2004) 218-225
6. Delacher S., Derendorf H., Hollenstein U., et al. A combined in vivo pharmacokinetic-in vitro pharmacodynamic approach to simulate target site pharmacodynamics of antibiotics in humans. J Antimicrob Chemother 46 (2000) 733-739
7. Mouton J.W., Vinks A.A., and Punt N.C. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob Agents Chemother 41 (1997) 733-738
8. Khunvichai. Pharmacokinetics and pharmacodynamics of faropenem daloxate. Doctoral thesis, University of Florida, 2003.
9. Schuck EL. Pharmacokinetics and pharmacodynamics of ciprofloxacin in simulated microgravity. Doctoral thesis, Department of Pharmaceutics, University of Florida, 2004.
10. Jain R., and Danziger L.H. The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview. Curr Pharm Des 10 (2004) 3045-3053
11. Burgess D.S., Hastings R.W., and Horan J.L. A time-kill evaluation of clarithromycin and azithromycin against two extracellular pathogens and the development of resistance. Ann Pharmacother 33 (1999) 1262-1265
12. Kucukbasmaci O., Gonullu N., Aktas Z., Gurol D., and Berkiten R. In vitro activity of telithromycin compared with macrolides and fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. Int J Antimicrob Agents 22 (2003) 497-501
13. Credito K.L., Lin G., Pankuch G.A., Bajaksouzian S., Jacobs M.R., and Appelbaum P.C. Susceptibilities of Haemophilus influenzae and Moraxella catarrhalis to ABT-773 compared to their susceptibilities to 11 other agents. Antimicrob Agents Chemother 45 (2001) 67-72
14. Hardy D.J., Hensey D.M., Beyer J.M., Vojtko C., McDonald E.J., and Fernandes P.B. Comparative in vitro activities of new 14-, 15-, and 16-membered macrolides. Antimicrob Agents Chemother 32 (1988) 1710-1719
15. Stille C.J., Andrade S.E., Huang S.S., et al. Increased use of second-generation macrolide antibiotics for children in nine health plans in the United States. Pediatrics 114 (2004) 1206-1211
16. Schuck E.L., and Derendorf H. Pharmacokinetic/pharmacodynamic evaluation of anti-infective agents. Expert Rev Anti Infect Ther 3 (2005) 361-373
17. Peters D.H., Friedel H.A., and McTavish D. Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy. Drugs 44 (1992) 750-799
18. Foulds G., Shepard R.M., and Johnson R.B. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 25 Suppl. A (1990) 73-82
19. Zhanel G.G., DeCorby M., Noreddin A., et al. Pharmacodynamic activity of azithromycin against macrolide-susceptible and -resistant Streptococcus pneumoniae simulating clinically achievable free serum, epithelial lining fluid and middle ear fluid concentrations. J Antimicrob Chemother 52 (2003) 83-88
20. Carbon C., and Poole M.D. The role of newer macrolides in the treatment of community-acquired respiratory tract infection. A review of experimental and clinical data. J Chemother 11 (1999) 107-118
21. Niederman M.S., Anzueto A., Sethi S., et al. Eradication of H. influenzae in AECB: a pooled analysis of moxifloxacin phase III trials compared with macrolide agents. Respir Med 100 (2006) 1781-1790
22. Lalak N.J., and Morris D.L. Azithromycin clinical pharmacokinetics. Clin Pharmacokinet 25 (1993) 370-374
23. Girard D., Finegan S.M., Dunne M.W., and Lame M.E. Enhanced efficacy of single-dose versus multi-dose azithromycin regimens in preclinical infection models. J Antimicrob Chemother 56 (2005) 365-371
24. Nightingale C.H. Pharmacokinetics and pharmacodynamics of newer macrolides. Pediatr Infect Dis J 16 (1997) 438-443
25. Amsden G.W. Advanced-generation macrolides: tissue-directed antibiotics. Int J Antimicrob Agents 18 Suppl. 1 (2001) S11-S15
26. Kays M.B., and Denys G.A. In vitro activity and pharmacodynamics of azithromycin and clarithromycin against Streptococcus pneumoniae based on serum and intrapulmonary pharmacokinetics. Clin Ther 23 (2001) 413-424
27. Hand W.L., and Hand D.L. Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes. Int J Antimicrob Agents 18 (2001) 419-425
28. Derendorf H, Gramatté, T, Schäfer, HG. Pharmakokinetik. Wissenschaftliche Verlagsgesellschaft mbH Stuttgart; 2002. p. 156.
29. Page II R.L., Ruscin J.M., Fish D., and Lapointe M. Possible interaction between intravenous azithromycin and oral cyclosporine. Pharmacotherapy 21 (2001) 1436-1443